Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 13

1.

Cancer statistics, 2012.

Siegel R, Naishadham D, Jemal A.

CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.

2.
3.

Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development: Workshop Summary.

Institute of Medicine (US) Roundtable on Translating Genomic-Based Research for Health.

Washington (DC): National Academies Press (US); 2011.

4.

Recommendations for the use of cardiac troponin measurement in acute cardiac care.

Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, Lindahl B, Giannitsis E, Hasin Y, Galvani M, Tubaro M, Alpert JS, Biasucci LM, Koenig W, Mueller C, Huber K, Hamm C, Jaffe AS; Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care.

Eur Heart J. 2010 Sep;31(18):2197-204. doi: 10.1093/eurheartj/ehq251. Epub 2010 Aug 3.

PMID:
20685679
5.

Translational research in cancer genetics: the road less traveled.

Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ.

Public Health Genomics. 2011;14(1):1-8. doi: 10.1159/000272897. Epub 2009 Dec 29.

6.

Evaluation of genetic tests for susceptibility to common complex diseases: why, when and how?

Wright CF, Kroese M.

Hum Genet. 2010 Feb;127(2):125-34. doi: 10.1007/s00439-009-0767-x. Epub 2009 Nov 20.

PMID:
19936793
7.

Use of archived specimens in evaluation of prognostic and predictive biomarkers.

Simon RM, Paik S, Hayes DF.

J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52. doi: 10.1093/jnci/djp335. Epub 2009 Oct 8.

8.

Mortality results from a randomized prostate-cancer screening trial.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

N Engl J Med. 2009 Mar 26;360(13):1310-9. doi: 10.1056/NEJMoa0810696. Epub 2009 Mar 18. Erratum in: N Engl J Med. 2009 Apr 23;360(17):1797.

9.

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO; EGAPP Working Group.

Genet Med. 2009 Jan;11(1):3-14. doi: 10.1097/GIM.0b013e318184137c.

10.

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium.

J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92.

PMID:
16954471
11.

Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.

U.S. Preventive Services Task Force.

Ann Intern Med. 2005 Sep 6;143(5):355-61. Review. Erratum in: Ann Intern Med. 2005 Oct 4;143(7):547.

PMID:
16144894
12.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L.

N Engl J Med. 2001 Mar 15;344(11):783-92.

13.

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG.

J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82.

PMID:
9390536

Supplemental Content

Support Center